Mainboard · BSE and NSEListed

Sai Parenteral’s Limited IPO: dates, price band, lot size, objects of the issue

Get analyst updates on this IPO

Analyst updates come by email.

What changed since listing, from SEBI-registered research analysts.

By continuing you agree to the Terms and Privacy policy

Updated Tue 17 Nov 2026, 10:51 am IST · Source: RHP dated Mon 16 Mar 2026

Bid dates
Tue 24 Mar 2026 to Fri 27 Mar 2026
Listing date
Thu 2 Apr 2026

Listed on BSE and NSE on Thu 2 Apr 2026.

Listing price ₹405

Opening price on BSE on the listing day (BSE daily price file for Thu 2 Apr 2026)

This page is now frozen. Facts stay as filed; the quote is on the exchange.

Key facts

Price band
Not stated in the RHP
RHP dated Mon 16 Mar 2026
Lot size
Not stated in the RHP
RHP dated Mon 16 Mar 2026
Lot amount at the upper band
Not stated in the RHP
RHP dated Mon 16 Mar 2026
Issue size at the upper band
Not stated in the RHP
RHP dated Mon 16 Mar 2026
Fresh issue
₹285.00 crore
RHP dated Mon 16 Mar 2026, page 1
Offer for sale
31,57,880 shares (Amount not stated in the RHP)
RHP dated Mon 16 Mar 2026, page 1
Bid dates
Tue 24 Mar 2026 to Fri 27 Mar 2026
RHP dated Mon 16 Mar 2026, page 2
Listing date
Thu 2 Apr 2026
BSE daily price file for Thu 2 Apr 2026
Final issue price
Set after bidding
RHP dated Mon 16 Mar 2026
Anchor lock-in ends
Set after bidding
RHP dated Mon 16 Mar 2026
Risk factors
93
RHP dated Mon 16 Mar 2026, page 92

Timeline (IST)

  1. OpensTue 24 Mar 2026, 10:00 am IST confirmedRHP dated Mon 16 Mar 2026, page 2
  2. ClosesFri 27 Mar 2026 confirmedRHP dated Mon 16 Mar 2026, page 2
  3. UPI mandate cut-offNot stated in the RHP RHP dated Mon 16 Mar 2026
  4. AllotmentMon 30 Mar 2026 by T+3 schedule
  5. Refund and unblockWed 1 Apr 2026 by T+3 schedule
  6. Shares to dematWed 1 Apr 2026 by T+3 schedule
  7. ListingThu 2 Apr 2026 confirmedBSE daily price file for Thu 2 Apr 2026

Objects of the issue

ObjectAmount
Capacity expansion and upgradation of manufacturing facilities₹110.80 crore
Establishment of a new R&D Centre₹18.02 crore
Repayment / prepayment of certain outstanding borrowings₹14.30 crore
Working capital requirements₹33.00 crore
Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia)₹35.64 crore
General corporate purposesNot stated in the RHP
TotalNot stated in the RHP

The offer for sale goes to the selling shareholders, not the company. RHP dated Mon 16 Mar 2026, page 132

Company and promoters

As described in the RHP

Our Company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. We are in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (“CDMO”) products and services for the domestic and international markets.

RHP dated Mon 16 Mar 2026, page 29

Promoters

  • 3 individual promoters

RHP dated Mon 16 Mar 2026, page 29

Shareholding

HoldingBefore the issueAfter the issue
Promoters and promoter group61.23%Not stated in the RHP

RHP dated Mon 16 Mar 2026, page 126

Financials (restated)

ItemSix months period ended September 30, 2025Fiscal 2025 (March 31, 2025)Fiscal 2024 (March 31, 2024)Fiscal 2023 (March 31, 2023)
Revenue from operations₹86.92 crore₹163.11 crore₹153.76 crore₹96.80 crore
Profit after tax₹7.76 crore₹14.45 crore₹8.42 crore₹4.38 crore
Net worth₹209.37 crore₹95.78 crore₹76.40 crore₹31.49 crore
Total borrowingsNot stated in the RHPNot stated in the RHPNot stated in the RHPNot stated in the RHP

RHP dated Mon 16 Mar 2026, page 97

Who is selling in the offer for sale

Selling shareholderTypeShares offeredAmount at the upper band
Vikasa India EIF I FundFund4,30,000Not stated in the RHP
Individual shareholderIndividual2,22,222Not stated in the RHP
Individual shareholderIndividual2,22,218Not stated in the RHP
Individual shareholderIndividual2,22,000Not stated in the RHP
Individual shareholderIndividual2,22,000Not stated in the RHP
Individual shareholderIndividual2,00,000Not stated in the RHP
Individual shareholderIndividual2,00,000Not stated in the RHP
Individual shareholderIndividual1,80,000Not stated in the RHP
Individual shareholderIndividual1,40,000Not stated in the RHP
Individual shareholderIndividual1,40,000Not stated in the RHP
Total offer for saleNot stated in the RHP

RHP dated Mon 16 Mar 2026, page 1

Peer comparison (as in the RHP)

Name of CompanyFace Value Per Share (₹)Closing price on February 03, 2026 (₹)Revenue from Operations for Fiscal 2025 (₹ million)EPS (₹) BasicEPS (₹) DilutedP/E (Times)EV/EBITDA (Times)MCap / Sales (Times)Return on tangible Net Worth (%)Net Asset Value per Equity Share (₹)
Company5[●]1,631.065.435.43[●][●][●]15.0935.98
Sai Life Sciences Limited1.00879.1516,945.708.838.61107.7040.6610.817.99102.12
Innova Captab Limited10.00727.2012,436.7622.4122.4132.4522.353.3513.37167.66
Senores Pharmaceuticals Limited10.00817.653,982.5016.1216.1264.3033.829.467.18176.37
Gland Pharma Limited1.001,895.7056,165.0442.4042.4044.7119.525.567.63555.41
Industry Average62.2929.097.29

Reproduced from the RHP dated Mon 16 Mar 2026, page 170; InsightPier adds no figures

Risk factors

93 total
  1. All manufacturing plants are in Hyderabad and Ongole, so local disruptions could hurt the business (RHP page 42)
  2. A large share of revenue comes from injectables, so lower demand for them could hurt results (RHP page 43)
  3. Plants face regulator and customer inspections that could lead to regulatory action (RHP page 44)
  4. No long-term supply contracts for raw materials; supply cuts or price swings could hurt results (RHP page 45)
  5. A few customers account for a large part of revenue; losing them could hurt the business (RHP page 47)

All 93 risk factors, RHP pages 42 to 92

Offer document

Allotment and bids

Registrar to the issue: Bigshare Services Private Limited.

Allotment status was expected on the registrar's site from Mon 30 Mar 2026 and is not yet confirmed. Pick "Sai Parenteral’s Limited" from the issue list there.

Research

Research reports on IPOs from SEBI-registered research analysts, published on InsightPier.

Research reports on IPOs from SEBI-registered research analysts